Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Roche's Bepranemab?
Bepranemab is a monoclonal antibody commercialized by Roche, with a leading Phase II program in Alzheimer's Disease. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Roche's Vanglusagene ensiparvovec?
Vanglusagene ensiparvovec is a gene therapy commercialized by Roche, with a leading Phase II program in Pompe Disease. According to...
Risk adjusted net present value: What is the current valuation of Roche's Inavolisib?
Inavolisib is a small molecule commercialized by Roche, with a leading Pre-Registration program in Human Epidermal Growth Factor Receptor 2...
Risk adjusted net present value: What is the current valuation of Roche's Ruzotolimod?
Ruzotolimod is a small molecule commercialized by Roche, with a leading Phase II program in Hepatitis B. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Roche's Rozlytrek?
Rozlytrek is a small molecule commercialized by Roche, with a leading Phase III program in Squamous Non-Small Cell Lung Cancer....